Dermata announces final patient enrolled in a phase 2 trial of dmt310 for the once-weekly treatment of moderate-to-severe rosacea

- topline results expected in the second half of 2022 - - rosacea affects about 16 million patients in the u.s. - san diego, ca / accesswire / june 13, 2022 / dermata therapeutics, inc. ("dermata," or the "company") (nasdaq:drma), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it has completed enrollment of its phase 2 trial of dmt310 for the once-weekly treatment of moderate-to-severe rosacea. dmt310 is dermata's lead product candidate, consisting of a once-weekly topical treatment, utilizing both mechanical and chemical mechanisms of action.
DRMA Ratings Summary
DRMA Quant Ranking